

LUNG-MAP

A lung cancer precision medicine trial

VOLUME 17 | SUMMER 2021

NEWSLETTER

WWW.LUNG-MAP.ORG

Lung-MAP at ASCO21 (and Beyond)

Lung-MAP researchers presented results from two sub-studies in poster sessions at the ASCO annual meeting in June. Karen Reckamp, MD, presented [toxicity data for S1800A](#), a non-match sub-study, and Jonathan Riess, MD, presented [results from sub-study S1900A](#).

Riess was also lead author on an editorial in the May 2021 issue of Clinical Lung Cancer: "[Novel Clinical Trial Designs in Pursuit of Precision Oncology: LUNG-MAP as a Model](#)." Christian Rolfo, MD, PhD, MBA, and David Gandara, MD, one of Lung-MAP's founding PIs, were coauthors.



Reckamp

Riess

Rolfo

Gandara


A Screening Choice: Previous FoundationOne CDx Results OR Tissue Submission?

Patients who previously had commercial FoundationOne CDx tissue testing done can now be screened for Lung-MAP sub-study assignment based on those results instead of submitting tissue. Results from a solid tumor FoundationOne CDx report done as early as September 1, 2019, can be reanalyzed by Foundation Medicine for Lung-MAP biomarker profiling.

You can start the reanalysis process using the SWOG Specimen Tracking System. [A step-by-step guide is available.](#)

This change means the informed consent document has also changed. It now includes several "OR" statements based on whether the patient is releasing tissue for testing or releasing previous results. Make sure your patients know which option they are consenting to.

Learn more on the [Lung-MAP training page](#). You can also contact the Lung-MAP data coordinators at LUNGMAPquestion@crab.org.



LEARN MORE AT
www.lung-map.org



A Look Ahead:

S1800D, a Lung-MAP non-match sub-study, is expected to activate by fall 2021. It will compare treatment with the combination of N-803 plus pembrolizumab to standard of care treatment for patients who have progressed on or after an anti-PD-1 or anti-PD-L1 therapy. The study was previewed at the spring 2021 SWOG group meeting, and a [recording of this presentation](#) is available (at the 43:25 timepoint).

As of 6/18/2021, the new LUNGMAP protocol has logged:

2065 screening registrations | **987** sub-study assignments | **290** sub-study registrations

TOP ACCRUING SITES*

1. UPMC Hillman Cancer Center	Pittsburgh, PA	125
2. UNM Comprehensive Cancer Center	Albuquerque, NM	39
3. Mercy Medical Center	Canton, OH	37
4. Wilmot Cancer Institute	Rochester, NY	33
5. Missouri Baptist Medical Center	St. Louis, MO	30
6. Roswell Park Comprehensive Cancer Center	Buffalo, NY	27
7. Markey Cancer Center	Lexington, KY	24
7. Good Samaritan Hospital	Cincinnati, OH	24
7. Stephenson Cancer Center	Oklahoma City, OK	24
8. Essentia Health	Duluth, MN	23
8. Virginia Cancer Institute	Richmond, VA	23
9. Northside Hospital Cancer Institute	Atlanta, GA	21
10. University of CA Davis Comprehensive Cancer Center	Sacramento, CA	20
10. Veterans Affairs Connecticut Healthcare System –	West Haven, CT	20
10. Robert H. Lurie Comprehensive Cancer Center of Northwestern University	Chicago, IL	20
10. Baystate Medical Center	Springfield, MA	20
10. Sparrow Hospital	Lansing, MI	20

*As of 6/18/21

CONTACT US

Protocol & Regulatory Questions
lgildner@swog.org or jbeeler@swog.org

Eligibility & Data Submission Questions
LUNGMAPQuestion@crab.org

General Medical Questions
LUNGMAP@swog.org

Central Monitoring Questions
centralmonitorquestion@crab.org

Quality Assurance Auditing Questions
qamail@swog.org

Funding Questions
funding@swog.org

S1900E Study Chairs
S1900EMedicalQuery@swog.org